BNP Paribas Financial Markets
ENZ

BNP Paribas Financial Markets’s Enzo Biochem, Inc. ENZ Stock Holding History

BNP Paribas Financial Markets’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-268
Closed -$860 – 4406
2021
Q4 		$860 Sell
268
-106
-28% -$362 ﹤0.01% 4064
2021
Q3 		$1.32K Sell
374
-3,908
-91% -$13K ﹤0.01% 3846
2021
Q2 		$13.6K Sell
4,282
-13,656
-76% -$42.9K ﹤0.01% 3643
2021
Q1 		$61.7K Buy
17,938
+9,827
+121% +$30.6K ﹤0.01% 3536
2020
Q4 		$20.4K Sell
8,111
-1,770
-18% -$3.85K ﹤0.01% 3843
2020
Q3 		$20.8K Buy
9,881
+7,099
+255% +$16.9K ﹤0.01% 3821
2020
Q2 		$6.23K Sell
2,782
-10,812
-80% -$27.8K ﹤0.01% 3912
2020
Q1 		$34.4K Buy
13,594
+3,144
+30% +$7.72K ﹤0.01% 3723
2019
Q4 		$27.5K Buy
10,450
+3,306
+46% +$9.88K ﹤0.01% 3910
2019
Q3 		$25.7K Buy
7,144
+41
+0.6% +$145 ﹤0.01% 3837
2019
Q2 		$23.9K Sell
7,103
-2,139
-23% -$7.54K ﹤0.01% 3834
2019
Q1 		$25.2K Buy
9,242
+8,581
+1,298% +$28.1K ﹤0.01% 3836
2018
Q4 		$1.84K Sell
661
-741
-53% -$2.43K ﹤0.01% 3819
2018
Q3 		$5.78K Buy
1,402
+79
+6% +$359 ﹤0.01% 3986
2018
Q2 		$6.87K Sell
1,323
-8,888
-87% -$54.2K ﹤0.01% 3953
2018
Q1 		$56K Buy
10,211
+1,521
+18% +$10.7K ﹤0.01% 3506
2017
Q4 		$70.8K Buy
8,690
+4,707
+118% +$45K ﹤0.01% 3479
2017
Q3 		$41.7K Sell
3,983
-214
-5% -$2.38K ﹤0.01% 3238
2017
Q2 		$46.3K Buy
4,197
+4,117
+5,146% +$38.4K ﹤0.01% 3238
2017
Q1 		$670 Sell
80
-474
-86% -$3.34K ﹤0.01% 3791
2016
Q4 		$3.85K Sell
554
-2,384
-81% -$15.2K ﹤0.01% 3793
2016
Q3 		$15K Buy
2,938
+1,369
+87% +$8.18K ﹤0.01% 3044
2016
Q2 		$9.37K Buy
+1,569
New +$8.71K ﹤0.01% 2943
2015
Q2 		– Sell
-1,295
Closed -$3.82K – 3635
2015
Q1 		$3.82K Buy
+1,295
New +$4.24K ﹤0.01% 3287
2014
Q4 		– Sell
-2,063
Closed -$10.6K – 3300
2014
Q3 		$10.6K Buy
2,063
+936
+83% +$4.99K ﹤0.01% 3555
2014
Q2 		$5.92K Hold
1,127
– – ﹤0.01% 2506
2014
Q1 		$4.73K Hold
1,127
– – ﹤0.01% 2418
2013
Q4 		$3.29K Buy
+1,127
New +$2.79K ﹤0.01% 3364

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

BNP Paribas Financial Markets's ENZ Position: Q1 2022 in Review

BNP Paribas Financial Markets sold out of Enzo Biochem, Inc. (ENZ) in Q1 2022, closing a stake of 268 shares — an estimated $860 sold.

BNP Paribas Financial Markets first reported a position in ENZ in Q4 2013 and held it in 28 quarters. The position peaked at $70.8K in Q4 2017. 51 funds tracked by Wall St. Rank hold ENZ as of Q1 2022.

  • BNP Paribas Financial Markets reported no remaining Enzo Biochem, Inc. position as of Q1 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 268 Enzo Biochem, Inc. shares in Q1 2022, an estimated $860.
  • BNP Paribas Financial Markets first reported a position in Enzo Biochem, Inc. in Q4 2013 and held it in 28 quarters.
  • BNP Paribas Financial Markets's Enzo Biochem, Inc. position peaked at $70.8K in Q4 2017.
  • 51 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2022, filed 17 May 2022.